Navigation Links
Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
Date:1/12/2011

CHAPEL HILL, N.C., Jan. 12, 2011 /PRNewswire/ -- Cempra Pharmaceuticals presented the broad spectrum and potent activity profile of solithromycin (CEM-101), the first fluoroketolide antibiotic, at the 5th Annual PHEMCE stakeholders workshop and Biomedical Advanced Research and Development Authority (BARDA) industry day on January 10 to 12 in Washington D.C.  

Solithromycin is a clinical-stage fluoroketolide antibiotic with potent and broad-spectrum activity against gram-positive and gram-negative pathogens, including multidrug-resistant strains, non-bacterial pathogens such as Plasmodium falciparum and a variety of bio-defense pathogens including Bacillus anthracis, Yersinia pestis, Burkholderia mallei and Francisella tularensis.  Phase 1 clinical studies with the oral formulation have shown excellent safety and tolerability and a pharmacokinetic profile that will enable once-daily dosing.  The oral formulation is undergoing a Phase 2 clinical trial in patients with community-acquired bacterial pneumonia (CABP).  An intravenous (IV) formulation of solithromycin is undergoing a safety and tolerability evaluation in a Phase 1 single and multiple dose escalation trial in healthy volunteers.  An oral pediatric suspension is also under development.

The presentation, delivered on January 12 by Jennifer Schranz, M.D., vice president of clinical affairs at Cempra Pharmaceuticals, described the potential utility of solithromycin as a bio-defense agent due to its broad antimicrobial spectrum, safety and tolerability, once-daily dosing, high tissue penetration, intracellular accumulation, and compound stability.  Data from mouse models were presented on the activity of once-daily solithromycin compared to an optimal dosing regimen of ciprofloxacin against B. anthracis and gentamicin against F. tularensis.  Solithromycin demonstrated activity comparable to c
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
2. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
3. Savient Pharmaceuticals Provides Business Update
4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Anadys Pharmaceuticals Augments Management Team and Board of Directors
6. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
7. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
9. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
10. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... (PRWEB) April 24, 2015 DryLet, ... use in applications such as animal waste reduction, ... oil reduction in wastewater treatment plants and restaurant ... exhibitor at the National Restaurant Association’s NRA Show ... , Representatives of the company will be available ...
(Date:4/24/2015)... April 24 , 2015 PAREXEL International ... services provider, today announced that Partnerships in Clinical Trials ... Management, the 2015 Clinical Innovator of the Year.  The ... team for the Company,s Perceptive MyTrials ® Data-Driven ... Thursday night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new ... packaging award from North America,s ... Competitor Comparison won Silver in the "Sustainability, service" ... The Brandcheck "Competitor Comparison" is a service ... North American and Global peers. This benchmarking process ...
(Date:4/23/2015)... Follow us on LinkedIn ... of genetic tests that determine individual susceptibility to ... Huntington's disease, and Alzheimer's disease. Predictive diagnostics are ... interaction in diseased tissue/cells to understand and determine ... response to treatment, such as in the numerous ...
Breaking Biology Technology:DryLet to Showcase Bio-React at the National Restaurant Association’s NRA Show 2015 May 16-19, 2015 in Chicago, Illinois 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3
... 21, 2011 United Therapeutics Corporation (Nasdaq: ... its FREEDOM-C(2) registration trial was completed on March ... multi-center, international, double-blind, randomized, placebo-controlled study of a ... in pulmonary arterial hypertension (PAH) patients receiving an ...
... Paul Braun,s lab look like any others, but they ... three-dimensional nanostructure for battery cathodes that allows for dramatically ... The researchers, findings will be published in the March ... Nanotechnology. Aside from quick-charge consumer electronics, batteries ...
... 18, 2011 Driving value for customers is critical to ... points between a customer and an organization, there has to ... an organization to succeed in the marketplace. ... Practices, LLC., noted in this month,s special issue of PharmaVoice ...
Cached Biology Technology:United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial 2Batteries charge quickly and retain capacity, thanks to new structure 2Batteries charge quickly and retain capacity, thanks to new structure 3Best Practices, LLC Showcases Its Expertise in Customer Relationship Management 2
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... smart wallets is underway to early access pre-order customers. ... includes usage at retail outlets including Walmart, Target, AT&T, ... report Wocket was accepted at all outlets and very ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... the frontal cortex in adults, researchers have shown that this ... actions. , It has been known for over 100 ... left frontal cortex, he or she often suffers difficulties in ... impairments, it has been difficult for researchers to test the ...
... high levels of antibodies against the Epstein-Barr virus, the ... likely to develop multiple sclerosis 15 to 20 years ... will appear in the June 2006 print issue of ... Researchers have long suspected that external factors may influence ...
... The cholesterol-lowering medications called statins do not appear to ... to a meta-analysis of previous studies in the January ... that statins reduce the risk of developing cancer, the ... "Statins have been studied in numerous large-scale, randomized, ...
Cached Biology News:Big hips, big belly? It's in your genes, Joslin-led study shows 2Statins have neutral effect on risk of cancer 2
...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
... The new Finnpipette Focus ... tip cone for pipetting from ... other narrow and long necked ... that whatever volume you select, ...
Biology Products: